20 articles
A major review outlines how targeted hematologic therapies are transforming outcomes in MGRS, a rare but serious cause of kidney injury.
A rigorous 2025 review finds no approved AMR therapy and reassesses all current evidence, spotlighting CD38 antibodies and complement inhibition.
Phase 1 trial examines whether vesatolimod can safely stimulate immune response in HIV controllers during treatment interruption.
A Phase II pilot trial tests whether adding carfilzomib to plasma exchange and IVIG can safely reverse antibody-mediated rejection after lung transplantation.
New research reveals efgartigimod reshapes B-cell populations in myasthenia gravis, inducing regulatory plasma cells linked to clinical improvement.
New research reveals how immune cells use cysteine for both antioxidant defense and energy production, with major implications for cancer treatment.
Systematic uric acid monitoring and treatment achieved 64% better remission rates than waiting for symptoms to guide therapy.
JAMA publishes a timely review of IgA nephropathy, the leading cause of primary glomerulonephritis worldwide, amid a wave of new therapies.
Pyruvate, a core metabolic molecule, suppresses interferon signaling by directly modifying STAT1 — linking metabolism to immune control.
Senescent cells drive cyst growth in ADPKD, and targeting them with senolytics or the aldose reductase inhibitor epalrestat delays disease progression.
Nephrologists from Canada and Ireland address clinical questions on IgA nephropathy, one of the most common causes of kidney failure worldwide.
New research reveals how a mitochondrial enzyme enhances immune cell function to fight bacterial lung infections and reduce inflammation.
A 2025 meta-analysis of 11 RCTs finds Tα1 reduces 28-day sepsis mortality overall, but high-quality trial data tells a more nuanced story.
A 2025 review from Johns Hopkins outlines how to accurately diagnose complement-mediated TMA using functional assays and systematic testing.
Whole genome sequencing of 7,339 Chinese participants uncovers novel genetic variants affecting serum uric acid, opening doors for precision therapies.
Revolutionary cell therapy achieves drug-free remission in patients with severe myasthenia gravis, an autoimmune muscle disorder.
A completed Phase 3 trial tests placental MSC secretome injections against placebo in 60 GvHD patients at an Iranian hospital.
Engineered immune cells offer new hope for treating kidney diseases that resist standard therapies, potentially improving long-term health outcomes.
GlaxoSmithKline tests a novel NS5B inhibitor across four dose groups in chronic HCV patients, evaluating safety and short-term antiviral activity.
New research reveals how granzyme A protein targets specific cells for pyroptosis, a form of programmed cell death crucial for immune defense.
